We are live on ! Find out more
KURA icon

Kura Oncology

182 hedge funds and large institutions have $474M invested in Kura Oncology in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 84 increasing their positions, 44 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 44

66% more call options, than puts

Call options by funds: $434K | Put options by funds: $261K

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

1% less funds holding

Funds holding: 183182 (-1)

4.79% less ownership

Funds ownership: 99.59%94.8% (-4.8%)

11% less capital invested

Capital invested by funds: $531M → $474M (-$57.3M)

Holders
182
Holders Change
-1
Holders Change %
-0.55%
% of All Funds
2.4%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
29
Increased
84
Reduced
44
Closed
29
Calls
$434K
Puts
$261K
Net Calls
+$173K
Net Calls Change
+$217K
Name Holding Trade Value Shares
Change
Change in
Stake
HWAM
51
Hennion & Walsh Asset Management
New Jersey
$1.07M +$405K +66,114 +55%
ACA
52
Apis Capital Advisors
New York
$1.04M +$1.1M +180,000 New
Jane Street
53
Jane Street
New York
$985K +$435K +70,934 +71%
Susquehanna International Group
54
Susquehanna International Group
Pennsylvania
$903K -$92.1K -15,032 -9%
GCM
55
Graham Capital Management
Connecticut
$854K -$163K -26,637 -15%
WP
56
Woodline Partners
California
$841K
IC
57
IEQ Capital
California
$824K +$275K +44,876 +46%
Jennison Associates
58
Jennison Associates
New York
$823K +$25.3K +4,130 +3%
GCP
59
GSA Capital Partners
United Kingdom
$819K +$692K +112,914 +389%
Invesco
60
Invesco
Georgia
$812K +$267K +43,515 +45%
D.E. Shaw & Co
61
D.E. Shaw & Co
New York
$812K -$1.7M -278,275 -66%
State of Wisconsin Investment Board
62
State of Wisconsin Investment Board
Wisconsin
$801K +$851K +138,846 New
Creative Planning
63
Creative Planning
Kansas
$786K +$422K +68,959 +102%
HSBC Holdings
64
HSBC Holdings
United Kingdom
$784K +$506K +82,585 +152%
Balyasny Asset Management
65
Balyasny Asset Management
Illinois
$783K +$831K +135,647 New
NRD
66
Nebula Research & Development
New York
$703K +$395K +64,460 +112%
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$686K +$83.9K +13,690 +13%
RC
68
Rangeley Capital
Connecticut
$669K +$711K +116,000 New
Swiss National Bank
69
Swiss National Bank
Switzerland
$668K +$162K +26,400 +30%
UBS Group
70
UBS Group
Switzerland
$648K -$167K -27,242 -20%
Rafferty Asset Management
71
Rafferty Asset Management
New York
$606K -$159K -25,988 -20%
RA
72
Rosalind Advisors
Ontario, Canada
$577K
TCM
73
Tang Capital Management
California
$577K
DekaBank Deutsche Girozentrale
74
DekaBank Deutsche Girozentrale
Germany
$557K
JP Morgan Chase
75
JP Morgan Chase
New York
$535K -$1.57M -256,326 -73%

KURA Hedge Fund Activity: Q2 2025 in Review

182 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2025, worth a combined $474M — down 11% from $531M a quarter earlier.

Fund positioning in KURA was balanced in Q2 2025: 29 funds opened new positions, 29 closed out, 84 added to existing stakes and 44 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $9.56M. The largest seller was RA Capital Management, exiting entirely with an estimated $26.4M sold.

  • 182 institutional investors held Kura Oncology (KURA) as of Q2 2025, down from 183 in Q1 2025.
  • Funds reported $474M of Kura Oncology stock for Q2 2025, down 11% quarter-over-quarter.
  • 29 funds opened new Kura Oncology positions in Q2 2025 and 29 closed out, a net change of 0 holders.
  • The largest Kura Oncology buyer in Q2 2025 was EcoR1 Capital, an estimated $9.56M added.
  • The largest Kura Oncology seller in Q2 2025 was RA Capital Management, an estimated $26.4M sold.

Based on aggregated 13F filings for Q2 2025.